千金药业发行股份购买资产方案获证监会批复同意

Core Viewpoint - The company plans to acquire a total of 28.92% equity in Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. and 68% equity in Hunan Qianjin Xieli Pharmaceutical Co., Ltd. through a combination of share issuance and cash payment [1] Group 1 - The company announced on September 12 that it received approval from the China Securities Regulatory Commission (CSRC) for the asset acquisition [1] - The CSRC has agreed to allow the company to issue 51.4449 million shares to specific investors for the acquisition of the related assets [1] - The share issuance and asset acquisition must comply with the application documents submitted to the Shanghai Stock Exchange and must be completed within 12 months [1]